Press Releases

Date Title and Summary Additional Formats
Toggle Summary Marinus Announces Positive Preliminary Data From Children With CDKL5 Genetic Disorder
Plans to Apply for Orphan Drug Designation RADNOR, Pa., Jan. 23, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), today announced positive preliminary data from the initial CDKL5 patients enrolled in its ongoing Phase 2 open-label study evaluating its CNS-selective GABA A...
View HTML
Toggle Summary Marinus Provides Business Outlook for 2017
Several Data Milestones Anticipated With Ganaxolone RADNOR, Pa., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a...
View HTML
Toggle Summary Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome
RADNOR, Pa., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the U.S....
View HTML
Toggle Summary Ganaxolone and Diazepam Administered Intravenously Synergistically Block Seizures in Animal Model of Status Epilepticus
Data Presented at Neuroscience 2016 RADNOR, Pa., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, presented preclinical data showing...
View HTML
Toggle Summary Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2016 Financial Results
RADNOR, Pa., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and other neuropsychiatric disorders, today provided a business update and announced its financial...
View HTML
Toggle Summary Ganaxolone Phase 1 Data Supports Progressing to Phase 2 in Patients with Status Epilepticus
Data Presented at the 141 st Annual Meeting of the American Neurological Association RADNOR, Pa., Oct. 19, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric...
View HTML
Toggle Summary Ganaxolone Reduces Seizures in Females with PCDH19 Pediatric Epilepsy
Positive Results from First Ever Proof-of-Concept Clinical Study in Children with the Rare Genetic Mutation of PCDH19...
View HTML
Toggle Summary Marinus Appoints Seth H.Z. Fischer to its Board of Directors
RADNOR, Pa., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced the appointment of Seth H.Z....
View HTML
Toggle Summary Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2016 Financial Results
RADNOR, Pa., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update and announced its financial results for...
View HTML
Toggle Summary Results from Phase 2 Exploratory Clinical Study Support Continued Development of Ganaxolone in Fragile X Syndrome
Anxiety and Hyperactivity Benefit shown in FXS Children Study Investigator to Participate in Conference Call and Webcast Today at 9:00 a.m. ET  RADNOR, Pa., June 28, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of...
View HTML